Polymyalgia Rheumatica Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Roche, Bristol Myers Squibb, Eli-lilly, Novartis, AbbVie, Sparrow Pharma, Chugai Pharma, AbbVie

The Key Polymyalgia Rheumatica Companies in the market include - Roche, Bristol Myers Squibb, Eli-lilly, Novartis, AbbVie, Sparrow Pharmaceuticals, Chugai Pharma, AbbVie, Janssen Research & Development, Sint Maartenskliniek, and others.

DelveInsight's "Polymyalgia Rheumatica Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Polymyalgia Rheumatica, historical and forecasted epidemiology as well as the Polymyalgia Rheumatica market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Polymyalgia Rheumatica market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Polymyalgia Rheumatica Market Forecast [https://www.delveinsight.com/sample-request/polymyalgia-rheumatica-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Polymyalgia Rheumatica Market Report:

*
The Polymyalgia Rheumatica market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In November 2024, Sparrow Pharmaceuticals, a clinical-stage biopharma company focused on developing targeted therapies for unmet needs in endocrinology and rheumatology, will present interim results from its ongoing Phase 2 trial of its lead candidate, clofutriben-a potent, selective HSD-1 inhibitor-combined with prednisolone for treating polymyalgia rheumatica (PMR) at the American College of Rheumatology Convergence 2024, held November 14-19 at the Walter E. Washington Convention Center in Washington, D.C. Additionally, Sparrow announced the expansion of the trial with a fifth cohort, following promising outcomes from the first four cohorts.

*
According to Duncan et al. the estimated prevalence of PMR, in the United States, is 1 in

*
133 people over the age of 50 years. The incidence of PMR and GCA increases with age, with a peak in those 70-80 years of age

*
According to Crowson 'et al' women accounted for 65 to 75% of patients. Polymyalgia rheumatica occurs at a frequency that is 3 to 10 times that of giant-cell arteritis

*
Key Polymyalgia Rheumatica Companies: Roche, Bristol Myers Squibb, Eli-lilly, Novartis, AbbVie, Sparrow Pharmaceuticals, Chugai Pharma, AbbVie, Janssen Research & Development, Sint Maartenskliniek, and others

*
Key Polymyalgia Rheumatica Therapies: Tocilizumab, Abatacept, Baricitinib, Secukinumab, ABBV-154, SPI-62, TCZ, Upadacitinib, Guselkumab, Rituximab, and others

*
The Polymyalgia Rheumatica epidemiology based on gender analyzed that the prevalence of Polymyalgia Rheumatica (PMR) is more among females as compared to males

*
The Polymyalgia Rheumatica market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Polymyalgia Rheumatica pipeline products will significantly revolutionize the Polymyalgia Rheumatica market dynamics.

Polymyalgia Rheumatica Overview

Polymyalgia rheumatica (PMR) is a rare inflammatory disease characterized by muscle pain (myalgia), stiffness, and additional generalized systemic symptoms such as fatigue, low-grade fever, and/or a general feeling of ill health (malaise). PMR can be a relatively benign condition that is extremely responsive to treatment.

Get a Free sample for the Polymyalgia Rheumatica Market Report

https://www.delveinsight.com/report-store/polymyalgia-rheumatica-market [https://www.delveinsight.com/report-store/polymyalgia-rheumatica-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Polymyalgia Rheumatica Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Polymyalgia Rheumatica Epidemiology Segmentation:

The Polymyalgia Rheumatica market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Polymyalgia Rheumatica

*
Prevalent Cases of Polymyalgia Rheumatica by severity

*
Gender-specific Prevalence of Polymyalgia Rheumatica

*
Diagnosed Cases of Episodic and Chronic Polymyalgia Rheumatica

Download the report to understand which factors are driving Polymyalgia Rheumatica epidemiology trends @ Polymyalgia Rheumatica Epidemiology Forecast [https://www.delveinsight.com/sample-request/polymyalgia-rheumatica-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Polymyalgia Rheumatica Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Polymyalgia Rheumatica market or expected to get launched during the study period. The analysis covers Polymyalgia Rheumatica market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Polymyalgia Rheumatica Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Polymyalgia Rheumatica Therapies and Key Companies

*
Tocilizumab: Roche

*
Abatacept: Bristol Myers Squibb

*
Baricitinib: Eli-lilly

*
Secukinumab: Novartis

*
ABBV-154: AbbVie

*
SPI-62: Sparrow Pharmaceuticals

*
TCZ: Chugai Pharma

*
Upadacitinib: AbbVie

*
Guselkumab: Janssen Research & Development

*
Rituximab: Sint Maartenskliniek

Discover more about therapies set to grab major Polymyalgia Rheumatica market share @ Polymyalgia Rheumatica Treatment Market [https://www.delveinsight.com/sample-request/polymyalgia-rheumatica-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Polymyalgia Rheumatica Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Polymyalgia Rheumatica Companies: Roche, Bristol Myers Squibb, Eli-lilly, Novartis, AbbVie, Sparrow Pharmaceuticals, Chugai Pharma, AbbVie, Janssen Research & Development, Sint Maartenskliniek, and others

*
Key Polymyalgia Rheumatica Therapies: Tocilizumab, Abatacept, Baricitinib, Secukinumab, ABBV-154, SPI-62, TCZ, Upadacitinib, Guselkumab, Rituximab, and others

*
Polymyalgia Rheumatica Therapeutic Assessment: Polymyalgia Rheumatica current marketed and Polymyalgia Rheumatica emerging therapies

*
Polymyalgia Rheumatica Market Dynamics: Polymyalgia Rheumatica market drivers and Polymyalgia Rheumatica market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Polymyalgia Rheumatica Unmet Needs, KOL's views, Analyst's views, Polymyalgia Rheumatica Market Access and Reimbursement

To know more about Polymyalgia Rheumatica companies working in the treatment market, visit @ Polymyalgia Rheumatica Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/polymyalgia-rheumatica-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Polymyalgia Rheumatica Market Report Introduction

2. Executive Summary for Polymyalgia Rheumatica

3. SWOT analysis of Polymyalgia Rheumatica

4. Polymyalgia Rheumatica Patient Share (%) Overview at a Glance

5. Polymyalgia Rheumatica Market Overview at a Glance

6. Polymyalgia Rheumatica Disease Background and Overview

7. Polymyalgia Rheumatica Epidemiology and Patient Population

8. Country-Specific Patient Population of Polymyalgia Rheumatica

9. Polymyalgia Rheumatica Current Treatment and Medical Practices

10. Polymyalgia Rheumatica Unmet Needs

11. Polymyalgia Rheumatica Emerging Therapies

12. Polymyalgia Rheumatica Market Outlook

13. Country-Wise Polymyalgia Rheumatica Market Analysis (2019-2032)

14. Polymyalgia Rheumatica Market Access and Reimbursement of Therapies

15. Polymyalgia Rheumatica Market Drivers

16. Polymyalgia Rheumatica Market Barriers

17. Polymyalgia Rheumatica Appendix

18. Polymyalgia Rheumatica Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=polymyalgia-rheumatica-market-predicted-to-see-upsurge-through-2032-highlights-delveinsight-roche-bristol-myers-squibb-elililly-novartis-abbvie-sparrow-pharma-chugai-pharma-abbvie]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.